Physicians Seek Unrestricted Coverage Of NaF-18 PET For Bone Metastasis
This article was originally published in The Gray Sheet
Recent shortages of an isotope commonly used in bone scans have prompted several professional societies to urge CMS to offer cancer patients broad access to sodium fluoride-18 positron emission tomography to identify bone metastasis
You may also be interested in...
CMS is proposing to cover positron emission tomography imaging for identification of bone metastasis in patients with a previously diagnosed solid tumor, but only as part of prospective clinical trials, the agency announced Nov. 30
Medicare coverage of PET scans for oncology indications will be less restrictive under a national coverage determination finalized April 3
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.